Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TAP Prevacid

Executive Summary

TAP is revising its 60-second "Heartbreak Hotel" ad in response to FDA objections. A March 15 letter from the ad division maintains that the ad did not sufficiently present the limitations to the indication for Prevacid or the side effect information. TAP has resolved the issue with the agency and a corrected version of the ad will run shortly, the Takeda/Abbott joint venture said
Advertisement

Related Content

Prevacid TV Ad Revisions Increase Prominence Of Indication After FDA Letter
Prevacid TV Ad Revisions Increase Prominence Of Indication After FDA Letter
Advertisement
UsernamePublicRestriction

Register

PS035831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel